Short Interest in Alterity Therapeutics Limited (NASDAQ:ATHE) Grows By 12.6%

Alterity Therapeutics Limited (NASDAQ:ATHE) saw a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 167,300 shares, an increase of 12.6% from the December 31st total of 148,600 shares. Currently, 2.0% of the shares of the company are short sold. Based on an average trading volume of 64,600 shares, the days-to-cover ratio is currently 2.6 days.

Institutional Trading of Alterity Therapeutics

An institutional investor recently raised its position in Alterity Therapeutics stock. HB Wealth Management LLC lifted its stake in Alterity Therapeutics Limited (NASDAQ:ATHE) by 34.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 31,883 shares of the company’s stock after purchasing an additional 8,100 shares during the quarter. HB Wealth Management LLC owned about 0.44% of Alterity Therapeutics worth $110,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 2.14% of the company’s stock.

Alterity Therapeutics Stock Up 2.0 %

Alterity Therapeutics stock traded up $0.10 during trading hours on Monday, hitting $4.90. 406,278 shares of the stock traded hands, compared to its average volume of 1,334,143. The firm’s 50 day moving average price is $2.78 and its 200-day moving average price is $1.83. Alterity Therapeutics has a 1 year low of $1.00 and a 1 year high of $5.87.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ATHE. Benchmark cut Alterity Therapeutics from a “speculative buy” rating to a “hold” rating in a research report on Monday. Maxim Group increased their price target on Alterity Therapeutics from $8.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday.

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.